Insulet (NSDQ:PODD) shares rose before the market opened today on fourth-quarter results that beat the consensus revenue forecast. The Acton, Mass.-based wearable insulin delivery system developer posted losses of -$17.1 million, or -26¢ per share, on sales of $246.1 million for the three months ended Dec. 31, 2020, for a bottom-line slide into the red on […]
Insulet
Insulet surpasses Q3 earnings estimates, raises guidance
Insulet (NSDQ:PODD) posted third-quarter results after market close yesterday that beat analysts’ consensus for the company. The Acton, Mass.-based tubeless insulin pump manufacturer announced profits of $11.6 million or $0.17 per share on sales of $234 million for the three months ended September 30, 2020, for a bottom-line gain of 13.5% on sales growth of 21% […]
How much is COVID-19 affecting procedure volumes for medtech?
UBS Financial Services released a report detailing how it expects medtech procedures to potentially keep dipping during the COVID-19 pandemic. The report highlighted a quicker-than-expected recovery in the second quarter after U.S. hospitals began canceling, delaying and deferring elective procedures in late March as the pandemic took hold. However, UBS still expects third-quarter medical procedures […]
MedTech 100 roundup: Another high as stocks tick up
For the third consecutive week, stocks in the medtech industry reached heights not yet seen since the COVID-19 pandemic began. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.65 points at the end of last week (Aug. 7). Overall, medtech stocks saw a 0.72% increase from […]
Insulet up on Street-beating Q2, raised guidance
Insulet (NSDQ:PODD) shares ticked up today on second-quarter results that topped the consensus forecast. The Acton, Mass.-based wearable insulin delivery system developer posted profits of $14.4 million, or 22¢ per share, on sales of $226.3 million for the three months ended June 30, 2020, for a bottom-line gain of nearly ten times as much as last […]
Insulet installs thousands of solar panels at global HQ
Insulet (NSDQ:PODD) announced today that its corporate headquarters and manufacturing facility will be powered by solar-based, renewable energy. The Acton, Mass.-based facility is set to turn to the new energy source, beginning this week. The company covered its 58,000 square-foot manufacturing facility with approximately 2,800 solar panels to, during optimal climate conditions, generate enough energy to […]
Insulet resumes next-gen Omnipod pivotal study following software issues
Insulet (NSDQ:PODD) today said it has resumed its pivotal study of its next-generation Omnipod Insulin Management System after pausing the study in March due to a software anomaly. The company paused the study about halfway through completion to correct an issue that could result in the system using an incorrect glucose value that had the potential […]
Insulet prices $500m public offering
Insulin management technology developer Insulet (NSDQ:PODD) announced that it priced a $500 million common stock offering. The Acton, Mass.-based company set the price of its common stock at $211 per share, with more than 2.3 million shares set to be sold. Insulet also granted underwriters a 30-day option to purchase up to 355,450 additional shares. Morgan […]
Insulet posts mixed bag Q1
Insulet (NSDQ:PODD) shares dropped slightly today on first-quarter results that topped the consensus revenue forecast but came up short on earnings. The Acton, Mass.-based insulin management technology developer posted losses of -$2.1, or -3¢ per share, on sales of $198 million for the three months ended March 31, 2020, for a bottom-line slide into losses from […]
DHS warns on Insulet Omnipod
The U.S. Dept. of Homeland Security (DHS) issued a medical advisory to warn of vulnerabilities with the Insulet (NSDQ:PODD) Omnipod insulin management system. According to the advisory, the affected insulin pumps are designed to communicate using a wireless RF with Insulet’s personal diabetes manager device, but the RF communication protocol does not properly implement authentication or […]
Insulet pauses OmniPod study due to software problem
Insulet (NSDQ:PODD) today said it is putting a halt on its pivotal study of its Omnipod Horizon Automated Glucose Control System because of a software anomaly. The company is correcting an issue that could result in the system using an incorrect glucose value that has the potential to impact insulin delivery, according to the company. Insulet […]
